JINYUAN HCHEM (02502.HK): H1 Revenue RMB 1.54bn, Up 7.0%; Profit RMB 41.6mn Turns to Profit
NewTimeSpace News: On 23 September 2026, Henan Jinyuan Hydrogenated Chemicals Co., Ltd. (the "Company") published its interim report for the six months ended 30 June 2026. Revenue amounted to approximately RMB 1,543.5 million (RMB 15.44 billion), up about 7.0% from RMB 1,442.2 million (RMB 14.42 billion) a year earlier; gross profit was about RMB 112.8 million (RMB 1.13 billion), up about fourfold; and profit for the period was about RMB 41.6 million, against a loss of about RMB 9.3 million a year earlier, turning to profit.
The announcement disclosed that the Group is a Henan-based supplier of hydrogenated phenyl chemicals and energy products, mainly engaged in processing crude benzene into pure benzene, toluene and xylene, and processing coke-oven gas into gas, liquefied natural gas (LNG) and hydrogen. During the period, the average selling price of hydrogenated phenyl chemicals rose from RMB 5,266.23/tonne to RMB 5,876.33/tonne and that of LNG from RMB 3,890.58/tonne to RMB 4,529.06/tonne, driving the sharp gross-profit improvement; gross margin rose from 1.6% to 7.3%.
The Company stated that as of 30 June 2026, total assets were about RMB 1,521.0 million (RMB 15.21 billion), slightly up from RMB 1,516.2 million at end-2025; total equity was about RMB 1,092.7 million (RMB 10.93 billion), up about 3.9% from RMB 1,051.2 million at end-2025. Basic EPS for the period was about RMB 0.04 (against a loss per share of RMB 0.02 a year earlier), and the Group declared no interim dividend.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- TIAN TU CAPITAL (01973.HK): Disclosed Transaction — Invests US$25m in Topos AI Infrastructure
- WAN KEI GROUP (01718.HK): Further Reallocates 2016 Placing Proceeds; HKD 3.4mn to Working Capital
- UBTECH ROBOTICS (09880.HK): Files CSRC Filing for H-share Full Circulation; 17.6m Shares to Convert
- SUNSHINE PHARMA (06887.HK): Files CSRC Filing for H-share Full Circulation; 38.9m Domestic Shares to Convert
- GENCH EDU (01525.HK): Independent Non-exec Director Changes; Shi & Zhang Appointed, Chen & Liu Resigned